DAREON™-8: A study to test how well different doses of BI 764532 in addition to standard of care are tolerated by people with advanced small cell lung cancer
1438-0008
Phase 1 other active
Quick answer
DAREON™-8: A study to test how well different doses of BI 764532 in addition to standard of care are tolerated by people with advanced small cell lung cancer for Extensive-stage small cell lung carcinoma (ES-SCLC) is a Phase 1 program (other) at Boehringer Ingelheim with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim
- Indication
- Extensive-stage small cell lung carcinoma (ES-SCLC)
- Phase
- Phase 1
- Modality
- other
- Status
- active